Research Article

NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and Metastasis

Figure 6

Estimation of tumor mutation burden (TMB) and immune checkpoint inhibitors by risk signature. (a, b) Analysis of the difference and correlation between tumor mutation burden and risk scores. (c, d) The effect of tumor mutation burden and risk scores on the overall survival of HCC patients. High risk scores were correlated with upregulated (e, f) PD-1 and (g, h) PD-L1, (i, j) CTLA4, and (k, l) LAG3 in HCC patients.
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)
(j)
(k)
(l)